Traws Pharma (NASDAQ:TRAW) Earns Neutral Rating from HC Wainwright

Traws Pharma (NASDAQ:TRAW)‘s stock had its “neutral” rating reiterated by research analysts at HC Wainwright in a report issued on Thursday,Benzinga reports.

A number of other equities analysts have also recently commented on TRAW. Citigroup cut Traws Pharma to a “neutral” rating in a report on Monday. Weiss Ratings cut Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a report on Friday, May 29th. Wall Street Zen raised Traws Pharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Finally, LADENBURG THALM/SH SH cut Traws Pharma from a “buy” rating to a “neutral” rating in a report on Monday. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $8.00.

Traws Pharma Stock Performance

Shares of Traws Pharma stock opened at $0.80 on Thursday. Traws Pharma has a one year low of $0.64 and a one year high of $3.27. The stock’s fifty day moving average is $1.44 and its 200 day moving average is $1.71. The stock has a market cap of $8.11 million, a P/E ratio of -0.47 and a beta of 1.45.

Traws Pharma (NASDAQ:TRAW) last announced its earnings results on Friday, May 15th. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.39. Analysts predict that Traws Pharma will post -1.58 EPS for the current year.

Insider Transactions at Traws Pharma

In other Traws Pharma news, major shareholder Orbimed Advisors Llc purchased 597,729 shares of the business’s stock in a transaction on Thursday, April 16th. The stock was acquired at an average price of $1.67 per share, for a total transaction of $998,207.43. Following the purchase, the insider owned 1,203,250 shares of the company’s stock, valued at approximately $2,009,427.50. This represents a 98.71% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 7.57% of the company’s stock.

Institutional Investors Weigh In On Traws Pharma

Institutional investors have recently bought and sold shares of the business. Two Sigma Investments LP increased its stake in Traws Pharma by 37.1% in the 3rd quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after buying an additional 5,955 shares in the last quarter. State Street Corp purchased a new position in shares of Traws Pharma during the fourth quarter valued at about $29,000. XTX Topco Ltd grew its position in shares of Traws Pharma by 294.2% during the fourth quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock valued at $48,000 after purchasing an additional 31,502 shares in the last quarter. Seven Fleet Capital Management LP purchased a new position in shares of Traws Pharma during the fourth quarter valued at about $56,000. Finally, Geode Capital Management LLC grew its position in shares of Traws Pharma by 41.9% during the fourth quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock valued at $70,000 after purchasing an additional 18,213 shares in the last quarter. Hedge funds and other institutional investors own 7.95% of the company’s stock.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.